The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000654358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/04/2026
Date registered
Help: Date registered
2/06/2026
Date last updated
Help: Date last updated
31/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
2/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Topical anti-Inflammatory Medication, for the management of Toe And Midfoot osteoarthritis: the TIMTAM randomised controlled trial
Scientific title
Topical anti-Inflammatory Medication, for the management of Toe And Midfoot osteoarthritis pain: the TIMTAM randomised controlled trial
Additional trial identifiers [1] 315061 0
Nil known
Universal Trial Number (UTN)
Trial acronym
TIMTAM
Related trial records

Health condition
Health condition(s) studied:
First metatarsophalangeal joint osteoarthritis 338436 0
Midfoot joint osteoarthritis 338437 0
Condition category
Condition code
Musculoskeletal 334733 334733 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention group will receive three 120g tubes of 23.2mg/g diclofenac gel. They will be instructed to apply a small amount gel (2g; approximately 5 cent piece size) to the painful area and rub it in until it has been absorbed, twice per day for 6 weeks. In the subsequent 6 weeks they will be advised that they may continue to use their allocated gel up to twice a day as needed on a symptomatic basis after the 6 week primary timepoint has been completed. Adherence will be monitored by the use of daily logbooks.
Intervention code [1] 331667 0
Treatment: Drugs
Description of the comparator or control
Participants in the control group will be provided with three 120g tubes of sham topical gel that is similar in appearance, smell and consistency to the intervention gel. They will be instructed to apply a small amount gel (2g; approximately 5 cent piece size) to the painful area and rub it in until it has been absorbed, twice per day for 6 weeks. In the subsequent 6 weeks they will be advised that they may continue to use their allocated gel up to twice a day as needed on a symptomatic basis after the 6 week primary timepoint has been completed. Adherence will be monitored by the use of daily logbooks.
Control group
Placebo

Outcomes
Primary outcome [1] 342384 0
Severity of foot pain during walking.
Timepoint [1] 342384 0
Baseline, 6 weeks (primary timepoint) and 12 weeks post-intervention commencement.
Secondary outcome [1] 450630 0
Foot Health Status Questionnaire (FHSQ) pain subscale
Timepoint [1] 450630 0
Baseline, 6 weeks and 12 weeks post-intervention commencement.
Secondary outcome [2] 450631 0
FHSQ physical function subscale
Timepoint [2] 450631 0
Baseline, 6 weeks and 12 weeks post-intervention commencement.
Secondary outcome [3] 450632 0
Severity of foot OA pain overall
Timepoint [3] 450632 0
Baseline, 6 weeks and 12 weeks post-intervention commencement.
Secondary outcome [4] 450633 0
Achievement of a global improvement in foot pain
Timepoint [4] 450633 0
6 weeks and 12 weeks post-intervention commencement.
Secondary outcome [5] 450634 0
Achievement of a global improvement in physical function
Timepoint [5] 450634 0
6 weeks and 12 weeks post-intervention commencement.
Secondary outcome [6] 450635 0
Quality of life (AQoL-6D)
Timepoint [6] 450635 0
Baseline, 6 weeks and 12 weeks post-intervention commencement.
Secondary outcome [7] 450636 0
Physical Activity Scale for the Elderly (PASE) score
Timepoint [7] 450636 0
Baseline, 6 weeks and 12 weeks post-intervention commencement.

Eligibility
Key inclusion criteria
i) aged >45 years,
ii) report foot pain in the first metatarsophalangeal joint and/or midfoot on most days of the month for the past 12 weeks,
iii) report a minimum foot pain score of 4 on an 11-point numerical rating scale during walking over the previous week,
iv) evidence of radiographic OA (a score of 2 or more for osteophytes or joint space narrowing according to a radiographic atlas) in either the first metatarsophalangeal joint and/or midfoot joints (the first cuneometatarsal (CM1) joint, the second CM (CM2) joint, the navicular–first cuneiform (N-1st C) joint, and the talonavicular (TN) joint), and
v) report either no morning joint-related stiffness in the big toe/midfoot joints, or morning stiffness that lasts no longer than 30 minutes.
Minimum age
45 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria

i) previous foot joint surgery or planned foot surgery on the affected side in the next 12 weeks,
ii) current use of any oral or topical anti-inflammatory medication for any condition (past 6 weeks),
iii) current contraindication to using topical anti-inflammatory medication (e.g., aspirin, allergy, anticoagulant use, salicylates, 3rd trimester of pregnancy, kidney problems, abdominal pain),
iv) had any foot joint injections on the affected side in the past 6 months or planned foot injections in next 12 weeks,
v) self-report any other current muscular, joint or neurological condition affecting lower limb function to such an extent that they are housebound or non-ambulant,
vi) pain in another foot or ankle location that is greater than the pain in the study foot joint,
vii) self-report any systemic or inflammatory joint disease (e.g., rheumatoid arthritis),
viii) moderate to severe hallux valgus based on a hallux abductus angle greater than 20 degs on x-ray,
ix) current (past 6 weeks) or planned use of a gait aid in the next 12 weeks,
x) current (past 6 weeks) or planned treatment with a health professional for their foot joint OA in the next 12 weeks,
xi) inability to understand written/spoken English,
xii) unable to commit to study requirements (e.g., attending x-rays, using gel, completing outcomes, unable to reach feet),
xiii) previously participated in a CHESM clinical trial in the prior four years, or currently participating in another research study at CHESM or elsewhere.


Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The person who will determine if a potential participant is eligible for inclusion in the trial will be unaware, when this decision is made, to which group the participant will be allocated. The randomisation schedule will be concealed in a password protected computer database. A member of the research team will maintain and access the schedule and reveal allocation to the Trial Coordinator as each participant requires randomisation.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomly allocated to the topical NSAID gel or the sham gel using a randomization schedule prepared by the study biostatistician. Randomization will occur according to a 1:1 allocation (permuted block sizes 6 to 12), stratified according to foot OA site (first MTP joint and midfoot). The schedule will be stored on a password-protected website (REDCap) maintained by a researcher not involved in either participant recruitment or administration of primary/secondary outcome measures. Group allocation will be revealed by this same researcher after baseline primary/secondary outcomes have been completed.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis
A total sample size of 148 (74 per arm) is required to detect the minimal clinically important difference (MCID) of 1.8 units in the primary outcome, change in walking pain on NRS, between groups with 90% power and an alpha of 0.05, assuming a conservative between-participant standard deviation (SD) of 2.6 and a correlation between baseline and 6-week post-intervention scores of 0.25 based on our previous RCT (ACTRN12623001304628) and with 20% attrition.

Data will be analysed on an intention-to-treat basis. A biostatistician (Li) will analyse blinded data according to a Statistical Analysis Plan that we will develop and publish on the CHESM website prior to data analysis commencing. Main comparative analyses between groups will be performed using intention-to-treat. Multiple imputation will be used if the primary outcome has greater than 5% missing data. For the primary outcome, differences in mean change in walking foot pain (baseline minus follow-up) will be compared between groups using a linear regression model, adjusted for baseline values and OA site (first MTP joint and midfoot). Continuous secondary outcomes will be analysed using similar approaches to the primary outcome. To aid clinical interpretation of the primary outcome, the proportion of participants in each group that show an improvement that reaches or exceeds the MCID in change in NRS walking foot pain (greater than or equal to 1.8 units) will be calculated and compared. For binary outcomes, groups will be compared using risk ratios and risk differences, using log-binomial regression models. The number of participants who experience a related adverse event will be compared between groups using Poisson regression. A sensitivity analysis will estimate treatment effects assuming full adherence (defined as applying the topical gel for =70% of the prescribed twice-daily application in the first 6 weeks), using an instrumental variables approach. Standard diagnostic plots will be used to check model assumptions.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC

Funding & Sponsors
Funding source category [1] 319628 0
Government body
Name [1] 319628 0
National Health And Medical Research Council
Country [1] 319628 0
Australia
Primary sponsor type
University
Name
The University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 322130 0
None
Name [1] 322130 0
Address [1] 322130 0
Country [1] 322130 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318188 0
Science, Technology, Engineering, Mathematics and Medicine (STEMM 2) – Greater Than Low Risk (GTLR) committee
Ethics committee address [1] 318188 0
Ethics committee country [1] 318188 0
Australia
Date submitted for ethics approval [1] 318188 0
13/08/2025
Approval date [1] 318188 0
31/03/2026
Ethics approval number [1] 318188 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 143394 0
A/Prof Kade Paterson
Address 143394 0
Centre for Health Exercise and Sports Medicine Department of Physiotherapy Level 7, Alan Gilbert Building, 161 Barry Street, Carlton, The University of Melbourne, VIC, 3010
Country 143394 0
Australia
Phone 143394 0
+61 3 8344 0425
Fax 143394 0
Email 143394 0
Contact person for public queries
Name 143395 0
Sam Shearer
Address 143395 0
Centre for Health Exercise and Sports Medicine Department of Physiotherapy Level 7, Alan Gilbert Building, 161 Barry Street, Carlton, The University of Melbourne VIC 3010
Country 143395 0
Australia
Phone 143395 0
+61 4 1163 6804
Fax 143395 0
Email 143395 0
Contact person for scientific queries
Name 143396 0
Kade Paterson
Address 143396 0
Centre for Health Exercise and Sports Medicine Department of Physiotherapy Level 7, Alan Gilbert Building, 161 Barry Street, Carlton, The University of Melbourne, VIC, 3010
Country 143396 0
Australia
Phone 143396 0
+61 3 8344 0425
Fax 143396 0
Email 143396 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
What types of analyses could be done with individual participant data?
• Meta analyses

When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
A finite period of: 15 years
Where can requests to access individual participant data be made, or data be obtained directly?
• From the principal researcher (email: [email protected]), with the appropriate Data Sharing Agreements as approved by the sponsor (the University of Melbourne).

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.